Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of aflibercept for an ophthalmic indication in Japan
jRCT2080221844Phase 3Completed
- Start
- Jul 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3 trial of aflibercept in well-being. Started Jul 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
well-being
Beyond the preview
Go deeper on jRCT2080221844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221844.